ABSTRACT
OBJECTIVE@#To study the change of TIZ expression in epithelial ovarian cancer cells.@*METHODS@#HO8910 cells were transinfected with siRNA to inhibit the expression of TIZ. pcDNA3.1-TIZ vectors were combined to increase the TIZ expression level. The cell viability, colony forming efficiency and cycle distribution of HO8910, HO8910/NC, HO8910/pcDNA3.1-NC, HO8910/TIZ-573 and H08910/pcDNA3.1-TIZ were compared, and the invasion rate, migration rate and adhesion rate between 5 groups of cells were compared.@*RESULTS@#Compared with those of HO8910, HO8910/NC and HO8910/pcDNA3.1-NC, the cell viability, colony forming efficiency and cell cycle distribution of HO8910/TIZ-573 were increased, while the indexes of H08910/pcDNA3.1-NC were decreased with statistical significant difference (P0.05).@*CONCLUSIONS@#The expression of TIZ can inhibit the proliferation of epithelial ovarian cancer cells.
ABSTRACT
Objective: To study the change of TIZ expression in epithelial ovarian cancer cells. Methods: HO8910 cells were transinfected with siRNA to inhibit the expression of TIZ. pcDNA3.1-TIZ vectors were combined to increase the TIZ expression level. The cell viability, colony forming efficiency and cycle distribution of HO8910, HO8910/NC, HO8910/pcDNA3.1-NC, HO8910/TIZ-573 and H08910/pcDNA3.1-TIZ were compared, and the invasion rate, migration rate and adhesion rate between 5 groups of cells were compared. Results: Compared with those of HO8910, HO8910/NC and HO8910/pcDNA3.1-NC, the cell viability, colony forming efficiency and cell cycle distribution of HO8910/TIZ-573 were increased, while the indexes of H08910/pcDNA3.1-NC were decreased with statistical significant difference (. P0.05). Conclusions: The expression of TIZ can inhibit the proliferation of epithelial ovarian cancer cells.
ABSTRACT
Objective: To explore the efficacy and safety of NAC (neoadjuvant chemotherapy) with docetaxel and cisplatin in patients with advanced epithelial ovarian cancer. Methods: Ninety-eight hospitalized patients with advanced ovarian cancer admitted to our hospital between January 2005 and July 2012 were randomly individed into NAC group (n = 48, receiving 2 cycles of NAC with docetaxel and cisplatin followed by cytoreductive surgery and 6 cycles of adjuvant chemotherapy with docetaxel and cisplatin) and the control group (n = 50, receiving cytoreductive surgery and 6-8 cycles of adjuvant chemotherapy with docetaxel and cisplatin). The mean blood loss, duration of operation and the rate of optimal cytoreductive surgery betweem the two groups were observed and compared. The side effects of chemotherapy and the survival were analyzed. Results: The amount of blood loss and the duration of operation of the NAC group were less than those of the control group (P < 0.05). The rate of optimal cytoreductive surgery of the NAC group was higher than that of the control group (85.4% vs 48.0%, P < 0.001). The median survival time and the median progression-free survival time were both longer than those of the control group (39 vs 31 months, P < 0.05; 27 vs 20 months, P < 0.05). The side effects of chemotherapy were not significantly different between the two groups. Conclusion: The NAC regimen with docetaxel and cisplatin can enhance the rate of optimal cytoreductive surgery, reduce the amount of blood loss, shorten the duration of operation, and improve the overall survival of patients with advanced epithelial ovarian cancer. Copyright © 2013 by TUMOR.
ABSTRACT
<p><b>BACKGROUND</b>The purpose of the study was to evaluate the role of neoadjuvant chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteries in treating patients with advanced ovarian epithelial carcinoma.</p><p><b>METHODS</b>Forty-two patients with advanced ovarian epithelial carcinoma (study group) were treated via the anterior branches of the bilateral internal iliac arteries after cytoreductive surgery and 7 courses of adjuvant platinum-based combination chemotherapy. Primary cytoreductive surgery was performed in 43 patients with advanced ovarian epithelial carcinoma (control group), and then followed by 8 courses of adjuvant platinum-based combination chemotherapy. The rate of optimal cytoreductive surgery, survival rate, blood loss during operation and operative time were investigated in the two groups. Statistical significance was assessed using Student's t test, the Chi-square test and the log-rank test.</p><p><b>RESULTS</b>In the study group, the rate of optimum debulking after platinum-based chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteries was 71.43% (30/42) (chi(2) = 10.06, P < 0.005), and 9 (21.43%) of the 42 patients showed no gross residual disease after surgery. Blood loss and operative time were significantly decreased in the study group as compared with those in the control group (665.24 +/- 37.61 ml: 849.31 +/- 41.20 ml, t(1) = 33.21, P(1) < 0.001; 4.23 +/- 0.21 hours: 6.15 +/- 0.38 hours, t(2) = 28.92, P(2) < 0.01). In the study group, the mean survival time and the median overall survival were 33.66 months (95% CI, 24.73 to 42.58) and 26.00 months (95% CI, 19.22 to 32.78), respectively. The median disease-free interval was 18.20 months. In the control group, the mean survival time and the median overall survival were 32.38 months (95% CI, 24.92 to 39.84) and 25.00 months (95% CI, 22.80 to 27.20), respectively. The median disease-free interval was 14.20 months. The overall survival rates were not significantly different between the two groups (chi(2) = 6.48, P > 0.05).</p><p><b>CONCLUSIONS</b>Neoadjuvant platinum-based combination chemotherapy and embolization via the anterior branches of the bilateral internal iliac arteries is an alternative treatment for patients with advanced ovarian epithelial carcinoma, in whom the chance of optimal cytoreductive surgery is low. The treatment can reduce blood loss, decrease operative time, and increase the rate of optimal cytoreductive surgery; but the median survival can't be improved significantly.</p>